Immediate infusional reactions to intravenous immunobiological agents for the treatment of autoimmune diseases: experience of 2126 procedures in a non-oncologic infusion centre.

Introduction: With the increasing use of immunobiological drugs (IBD), the knowledge about their effectiveness and safety has increased.

Objective: To analyze the immediate infusional reactions (IIR) to intravenous IBD: infliximab (IFX), rituximab (RTX), abatacept (ABT) and tocilizumab (TCZ) on the treatment of autoimmune diseases.

Method: 2126 infusions performed in the Infusion Centre - CID in 268 patients were analyzed.